The research takes a closer look at prominent factors driving the growth rate of the prominent product categories across major geography. Furthermore, the study covers a lot of the sales, gross margin, consumption capacity, spending power and customer preference across various countries. The report offers clear indications how the Minimally Invasive Biopsy Technologies market is expected to witness numerous exciting opportunities in the years to come. Critical aspects including the growing requirement, demand and supply status, customer preference, distribution channels and others are presented through resources such as charts, tables, and infographics. The Global Minimally Invasive Biopsy Technologies Market is projected to reach USD 3.98 billion in 2027.
You Can
Download Free Sample PDF Copy of Minimally Invasive Biopsy Technologies Market
at https://www.emergenresearch.com/request-sample/75
Further
key findings from the report suggest
The ambulatory surgery centers have a more convenient
outpatient procedure alternative to the hospital-based inpatient systems,
maintaining a strong track record of quality care. Ambulatory surgery centers,
incorporating all the required and modern MIB technologies, are expected to grow
fastest amongst the end-use verticals throughout the forecast period.
The therapeutic application is further segmented into Lung
Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, and
Non-oncology Application. Minimally invasive breast biopsy (MIBB) has been
highly recommended for the pre breast cancer diagnosis and checkup globally.
The MIBB is expected to grow higher during the projected period as the number
of breast cancer increases.
The Asia Pacific region, due to its immense rise in the
breast & lung cancers & rising usage of the MIB technologies, is
expected to accelerate with the fastest growth rate of 20.1% during the
projected period 2020 to 2027.
Key
players in the market include Chronix Biomedical, Biocept,
Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc., Thermo
Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive
Biotechnologies, and Owlstone Medical Ltd., among others.
Technology
Outlook (Revenue: USD Billion; 2017-2027)
Liquid Biopsy
Optical Biopsy
Brush Biopsy
Pigmented Lesion Assays
Breath Biopsy
Brush Biopsy
Others
Therapeutic
Application Outlook (Revenue: USD Billion; 2017-2027)
Lung Cancer
Breast Cancer
Prostate Cancer
Colorectal Cancer
Blood Cancer
Non-oncology Applications
End-Use
Verticals Outlook (Revenue: USD Billion; 2017-2027)
Hospitals & Clinics
Ambulatory Surgical Centers
Cancer Research Institutes
Others
Regional
scope: North America; Europe; Asia Pacific; Central & South
America; MEA
Read
more@ https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market
Table
of Content
Chapter 1. Methodology & Sources
1.1. Market
Definition
1.2. Research
Scope
1.3. Methodology
1.4. Research
Sources
1.4.1.
Primary
1.4.2.
Secondary
1.4.3. Paid
Sources
1.5. Market
Estimation Technique
Chapter 2. Executive Summary
2.1. Summary
Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Minimally Invasive Biopsy Technologies Market
Segmentation & Impact Analysis
4.1. Minimally
Invasive Biopsy Technologies Market Material Segmentation Analysis
4.2. Industrial
Outlook
4.2.1. Market
indicators analysis
4.2.2.
Market drivers analysis
4.2.2.1. Growing demand for growing medicinal application
4.2.2.2. Rising legalization of Minimally Invasive Biopsy Technologies
4.2.2.3. Technological advancement in product invention
4.2.3.
Market restraints analysis
4.2.3.1. The complex regulatory framework for the usage of Minimally
Invasive Biopsy Technologies
4.3. Technological
Insights
4.4. Regulatory
Framework
4.5. Porter’s Five
Forces Analysis
4.6. Competitive
Metric Space Analysis
4.7. Price trend
Analysis
4.8. Covid-19
Impact Analysis
Continued…
No comments:
Post a Comment